Lumacaftor monotherapy

Drug Profile

Lumacaftor monotherapy

Alternative Names: Corrector VX-809; VRT-826809; VX-809

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Cystic Fibrosis Foundation Therapeutics; Vertex Pharmaceuticals
  • Developer Vertex Pharmaceuticals
  • Class Amides; Benzodioxoles; Benzoic acids; Cyclopropanes; Pyridines; Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Cystic fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cystic fibrosis

Most Recent Events

  • 21 Jul 2016 Biomarkers information updated
  • 06 Oct 2015 Discontinued - Phase-III for Cystic fibrosis in Canada, Belgium, Netherlands, Germany, USA (PO)
  • 19 Nov 2014 Royalty Pharma acquires royalties on lumacaftor from Cystic Fibrosis Foundation Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top